Evidence map›Paper›PMID 34406634›Full record

ReviewNeuromolecular medicine2022

Emerging Therapeutic Strategies for Brain Tumors.

Muna Aryal, Tyrone Porter

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuromolecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Muna AryalDepartment of Engineering, Loyola University Chicago, Chicago, IL, USA.
Tyrone PorterDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA. tmp6@utexas.edu.ORCID 0000-0002-7239-4091
Loyola University Chicago · USThe University of Texas at Austin · US

Funding

Focal ultrasound-mediated nonthermal ablation of brain tumorsR21EB027506 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI PORTER, TYRONE · 2019 to 2020
$492k
NIBIB NIH HHS R21 EB027506
6 · The paper itself

Abstract

Nearly thirty thousand incidences of primary and 300 thousand incidences of metastatic brain cancer are diagnosed in the USA each year. It has a high mortality rate and is often unresponsive to the standard of care, which includes surgical resection, radiation, and chemotherapy. These treatment strategies are also hindered by their invasiveness and toxic effects on healthy cells and tissues. Furthermore, the blood-brain/tumor barrier severely limits delivery of anti-cancer therapeutics administered intravenously to brain tumors, resulting in poor tumor response to the treatment. There is a critical need to develop new approaches to brain cancer therapy that can overcome these limitations. Focused ultrasound has emerged as a modality that addresses many of these limitations and has the potential to alter the treatment paradigm for brain cancer. Ultrasound transmitted through the skull can be focused on tumors and used for targeted ablation or opening the vascular barriers for drug delivery. This review provides insight on the current status of these unique ultrasound techniques, different strategies of using this technique for brain cancer, experience in preclinical models, and potential for clinical translation. We also debate the safety perspective of these techniques and discuss potential avenues for future work in noninvasive planning, monitoring, and evaluation of the ultrasonic neurointervention.

Indexed as

Blood-Brain BarrierBrain NeoplasmsBiological TransportBrainDrug Delivery SystemsHumansMagnetic Resonance ImagingBBB disruptionBrain cancerMR thermometryPassive cavitation detectionPassive cavitation imagingTranscranial focused ultrasoundTumor ablation

Identifiers

PMID34406634
OpenAlexW3195381210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.